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Allogeneic hematopoietic stem cell transplantation (HSCT) can be performed across the ABO blood group
barrier. The impact of ABO incompatibility on clinical outcome is controversial. A retrospective analysis of 310
patients who underwent HSCT with reduced-intensity conditioning between 1998 and 2011 was performed
to investigate the frequency and clinical implications of anti-RBC antibodies in passenger lymphocyte syn-
drome (PLS) after minor ABO mismatch (mm), persistent or recurring recipient type ABO antibodies (PRABO)
after major ABO mm HSCT, and autoimmune hemolytic anemia (AIHA). Transplantation characteristics and
clinical outcome were analyzed by univariate and multivariate analysis for groups with or without anti-RBC
antibodies. ABO blood group incompatibility did not affect clinical outcome despite an increased requirement
of blood transfusion. Twelve patients with AIHA, 6 patients with PLS, and 12 patients with PRABO post-HSCT
were identiﬁed. AIHA did not affect overall survival (OS) or transplant-related mortality (TRM), but patients
with AIHA had a lower incidence of grades II to IV acute graft-versus-host disease (P ¼ .05). OS in the PLS
group was 0% compared with 61% in the whole group receiving minor ABO mm transplants (P < .001).
Comparing PRABO patients with those receiving a major ABO mm HSCT, the OS was 17% versus 73% (P ¼ .002)
and TRM was 50% versus 21% (P ¼ .03). At our center, PLS after minor ABO mm and PRABO antibodies after
major ABO mm HSCT are signiﬁcant risk factors for decreased OS and TRM. Our results suggest that occur-
rence of unexpected ABO antibodies after HSCT warrant a wider investigation individual to ﬁnd the under-
lying cause.
 2014 Published by Inc. on behalf of American Society for Blood and Marrow Transplantation.INTRODUCTION engraftment time and lower general IgM and IgG concen-
Allogeneic hematopoietic stem cell transplantation
(HSCT) is a successful treatment strategy for hematopoietic
malignancies and inborn errors of metabolism or the im-
mune system [1]. In contrast to organ transplantation, HSCT
is more readily performed across the ABO blood group bar-
rier [2-7]. The impact of ABO incompatibility on clinical
outcome after HSCT has been debated. A database study from
the Center for International Blood and Marrow Transplant
Research reported no impact of ABO incompatibility on pa-
tient survival or transplant-related mortality (TRM); how-
ever, the duration of RBC transfusion was prolonged in the
major ABO-incompatible group [8]. In contrast, several
single-center studies indicated that ABO incompatibility may
have impact on clinical outcome and can occasionally give
rise to severe hemolytic complications. Nonetheless, results
remain conﬂicting, and the patient materials in these studies
are heterogeneous [9-11]. ABOmismatch (mm) in cord blood
transplantations has been correlated both to increasededgments on page 269.
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After reduced-intensity conditioning (RIC), there is a
prolonged period where a mixture of recipient and donor
lymphocytes coexist and, consequently, two different
antibody-producing immune systems [14-16]. Antibodies
against naturally occurring ABO-associated antigens can
cause severe hemolytic complications after ABO-incompat-
ible HSCT. Passenger lymphocyte syndrome (PLS) and
persistent or recurring recipient type ABO antibodies
(PRABO) sometimes cause delayed donor erythropoiesis
[17-20]. Autoimmune hemolytic anemia (AIHA), in which
donor lymphocytes produce autoantibodies against donor
antigens, has also been described after HSCT [21]. Treatment
strategies and transfusion requirement associated with these
complications differ between centers [2,22].
In this study, we aimed to investigate the impact of ABO
mm on clinical outcome in 310 patients after HSCT receiving
RIC. We also investigated the prevalence and clinical impli-
cations of anti-RBC antibodies of donor and recipient origin.
METHODS
Patients
Four hundred twenty-four consecutive patients who underwent HSCT
received RIC between January 1998 and August 2011 at our institution. Of
these, 114 patients with early malignant relapse (<12 months) or those
retransplanted were excluded because of short follow-up time, leaving 310
patients for analysis. All patients provided informed consent, and the studyociety for Blood and Marrow Transplantation.
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follow-up was 24 months (range, .2 to 151 months) for all patients and
46 months (range, 1.4 to 151 months) for surviving patients.
HLA typingwas performed by 6-digit high-resolution typing for HLA class
I (A, B, and C) and HLA class II (DRB1, DQB1, and DPA) [23]. Four patients were
transplanted with an HLA mismatched related donor, and 21 patients were
transplanted with a mismatched unrelated donor. Conditioning regimens
were based on protocols determined by disease requirements. Only patients
who received RIC were included. Conditioning protocols were as follows:
ﬂudarabine 30 mg/m2/d for 3 to 6 days in combination with cyclophospha-
mide 60mg/kg/d for 2 days (n¼ 67), with 2 3 Gy total body irradiation and
cyclophosphamide 60 mg/kg/d for 2 days (n ¼ 50), with 2 Gy total body
irradiation (n ¼ 36), with treosulfan 14 g/m2 for 3 days (n ¼ 45) or 4 mg/kg/
d busulfan for 2 days (n ¼ 108). All patients with an unrelated donor or a
nonmalignant disorder were given antithymocyte globulin (ATG) 4 to 8 mg/
kg as part of conditioning (n¼ 225). Rabbit ATGwas used for 203 patients and
Campath for 22 patients. Rabbit-ATG was given for 2 to 4 days, 2 mg/kg/day,
and Campath 30 mg/day for 1 to 3 days [24]. For patient details, see Table 1.
Graft-versus-host disease (GVHD) prophylaxis consisted of cyclosporine
A (CsA) in combination with methotrexate (n ¼ 196), prednisolone (n ¼ 12),
or mycophenolate mofetil (n ¼ 29) [25]. Sirolimus and tacrolimus were
given to 49 patients, and 12 received mycophenolate mofetil and tacrolimus
[26]. Seven patients received CsA þ methotrexate and cyclophosphamide
(50 mg/kg) on days 3 to 4 after HSCT. During the ﬁrst month, blood CsA
levels were maintained at 100 ng/mL or 200 to 300 ng/mL for a sibling or
unrelated donor, respectively. In the absence of GVHD, CsAwas discontinued
after 6 months in patients with malignancies and after 12 to 24 months inTable 1
Patient Characteristics
ABO Match
(n ¼ 145)
Minor mm
(n ¼ 66)
Major mm
(n ¼ 95)
P
Age 48 (<1-68) 53 (1.5-71) 53 (<1-77) ns
Sex (M/F) 85/60 45/21 49/46 ns
Diagnosis
Nonmalignant 36 5 19 .05
Acute leukemia 29 9 17 ns
Chronic leukemia 16 13 10 ns
Lymphoma 14 9 10 ns
Myeloma 8 1 5 ns
Solid tumor 24 18 17 ns
MDS 14 8 11 ns
Myeloﬁbrosis 4 3 6 ns
Stage* (early/late) 73/48 20/28 43/35
Donor
Sibling/MUD/mm 73/61/11 20/42/4 28/57/10 ns
Donor age 39 (0-71) 36 (0-72) 35 (0-67) ns
Donor sex (M/F) 81/64 44/21 56/39 ns
Female-to-male 28 (19%) 9 (14%) 10 (11%) ns
Conditioning ns
FluþTBI 2 Gy 21 5 10
FluþBu 55 19 34
FluþCy 25 25 17
FluþCyþTBI 22 8 20
FluþTreo 22 9 14
ATG 100 51 74 ns
GVHD prophylaxis ns
CsAþMTX 90 43 63
Prografþsirolimus 25 10 14
Other 30 13 18
Stem cell source
BM/PBSC/CB 30/108/7 11/53/2 19/71/5 ns
ns indicates not signiﬁcant; MDS, myelodysplastic syndrome; MUD,
matched unrelated donor; Flu, ﬂudarabine; TBI, total body irradiation; Bu,
busulfan; Cy, cyclophosphamide; Treo, treosulfan; MTX, methotrexate; BM,
bone marrow; PBSC, peripheral blood stem cells; CB, cord blood.
Nonmalignant disease consists of patients with severe aplastic anemia
(n ¼ 11), Fanconi (n ¼ 8), congenital immunodeﬁciencies (n ¼ 9), Parox-
ysmal nocturnal hemoglobinuria, PNH (n ¼ 3), Hurler (n ¼ 1), familial
haemophagocytic lymphohistiocytosis, FHL (n ¼ 9), thalassemia (n ¼ 4),
Metachromatic Leukodystrophy, MLD (n ¼ 1), chronic granulomatous dis-
ease, CGD (n¼ 5), Kostman (n¼ 4), WAS (n¼ 1), erythropoietic protoporfyri
(n ¼ 1), and Maroteauz Lamy (n ¼ 1). Solid tumors were patients with
kidney (n ¼ 21), colon (n ¼ 16), liver (n ¼ 15) prostate (n ¼ 3), and
pancreatic (n ¼ 4) cancers.
* Early stage: CR1/CP1 or nonmalignant disorder; Late stage: beyond CR1/
CP1.patients with nonmalignant disorders [27]. For nonmalignant patients with
sibling donors, CsA was discontinued after 3 months.
Supportive Care
Patients either were treated in reversed isolation in the HSCT ward for
the duration of the transplantation process until engraftment or were given
conditioning treatment in the ward and followed at home according to our
home care program [28]. Supportive care has been described in detail pre-
viously [28]. All patients considered to be high risk for developing Epstein-
Barr virus (EBV)epost-transplant lymphoproliferative disorder were
screened weekly or biweekly for EBV during the ﬁrst 3 months post-HSCT.
Patients with serological EBVmismatch, umbilical cord blood grafts, primary
EBV infection in patient or donor close to HSCT, and lymphoma or chronic
lymphocytic leukemia were considered to be high risk. In low-risk patients,
quantitative PCR was performed on suspicion of EBV reactivation [29].
Engraftment was deﬁned as the ﬁrst of 3 consecutive days with an ab-
solute neutrophil count of 0.5  109/L or more. Platelet engraftment was
deﬁned as the ﬁrst of 3 consecutive days with a platelet count of 50  109/L
or more without platelet transfusion. Graft failure was deﬁned as failure to
produce donor hematopoietic cells measured by chimerism analysis as
previously described [9].
Transfusion Policy
RBCs were usually transfused if hemoglobin levels were <80 g/L, and
platelets were transfused at platelet counts < 10  109/L [30]. All blood
components were leukocyte reduced through prestorage ﬁltration and
irradiated with 25 Gray. The blood components transfused at the time of
HSCTand afterwere ABO and RhD compatible with both donor and recipient
blood groups [14,31]. Platelet transfusion practices, with regard to ABO
blood groups, vary globally. At our center, platelet transfusions were
considered compatible following the same recommendations for ABO blood
groups as RBCs [32]. Platelets were derived from buffy coats or from
apheresis. Buffy coat platelets consist of buffy coats prepared from 5 to 6
donors per unit with platelet additive solution added up to two thirds of the
ﬁnal volume [33,34]. Apheresis platelets were suspended in plasma, but
blood group O donors were screened to avoid that units from donors with
high anti-A/anti-B titers were given to patients with other blood groups.
Blood Group Serology
ABO blood typing was performed according to established routine
methods using an automated system (AutoVue; Ortho Clinical Diagnostics,
Raritan, NJ) or manually using tubes or gel technique (Bio-Rad Laboratories,
Herts, UK). A direct antiglobulin test (DAT) was analyzed using a manual
tube method (AABB TechnManual 16th ed p.908, Bethesta MD, USA) or a gel
technique (ID-Liss Coombs, DC-Screening I; Bio-Rad Laboratories) or with
the automated AutoVue system (Ortho Clinical Diagnostics). An indirect
antiglobulin test was performed with a gel technique (ID-Coombs Anti-IgG;
Bio-Rad Laboratories) or with the AutoVue system (antihuman globulin,
AHG anti-IgG). Cold acid eluates fromRBCs were prepared using the ELU-KIT
II (Gamma Biologicals, Houston, TX) according to the manufacturer’s in-
struction. In case of major ABO incompatibility, the recipient ABO antibody
titer was determined before HSCT using a standard tube technique (until
2005) or a gel technique (from 2005) against donor RBCs if available;
otherwise, RBCs of a surrogate donor with the same ABO blood group were
used.
To screen and diagnose PLS after minor ABOmm, HSCT, DAT, and reverse
blood grouping were performed as part of a pretransfusion compatibility
testing during the ﬁrst month post-HSCT. Screening for the existence of
PRABO after major ABO mm HSCT or for AIHA was not routinely done. DAT
and antibody investigation were performed if hemolysis was clinically
suspected and/or if there was an extensive transfusion need. Until 2009, all
patients were routinely RBC phenotyped for donor and recipient markers
before HSCT and at 3, 6, and 12 months after HSCT to monitor engraftment
together with chimerism analysis for T, B, and myeloid lineages. After 2009,
only leukocyte chimerism for T, B, and myeloid lineages were used to
monitor persistent donor engraftment.
Deﬁnitions
In an ABO major incompatible HSCT, the recipient has ABO antibodies
against donor ABO antigens, that is, when the donor is blood group A, B, or
AB to a blood group O recipient or a blood group AB donor to a blood group A
or B recipient. In an ABO minor incompatible HSCT, the donor has ABO
antibodies against recipient ABO antigens. In this case, the donor is blood
group O and the recipient is A, B, or AB or the donor is blood group A or B and
recipient AB. In bidirectional ABO incompatibility, there is a simultaneous
major and minor mm, that is, the donor is blood group A and the recipient B
and/or vice versa.
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either on the recipient’s RBCs or in recipient plasma during the ﬁrst
month after minor ABO mm HSCT. PRABO was deﬁned as patients having
recipient type anti-A and/or anti-B still detectable in plasma or on RBCs
more than 3 months after major ABO mm HSCT. AIHA was deﬁned as pa-
tients with positive DAT and non-ABO autoantibodies detected by the in-
direct antiglobulin test after HSCT.
HLA mm was deﬁned as any disparity in HLA-A, -B, or -DRB1 between
donor and recipient. The serostatus in recipients of the herpes viruses EBV,
cytomegalovirus, herpes simplex virus types 1 and/or 2, and varicella zoster
virus was determined in the recipients at the time of HSCT. Patients were
divided in 2 groups and compared if theywere seropositive for 0 to 2 or 3 to 4
of the viruses. Herpes simplex virus types 1 and 2 were considered as 1 virus.Statistics
Clinical data from each patient documented in the Transfusion Medicine
Laboratory Information System was retrospectively analyzed for DAT and
indirect antiglobulin test results, transfusion history, and presence of anti-
ABO antibodies. The number of transfused RBCs and platelet units during
the ﬁrst 2 and 12 months post-HSCT, respectively, were noted. Patients who
fulﬁlled criteria for PLS, PRABO, or AIHA were identiﬁed.
Overall survival (OS) was calculated using the Kaplan-Meier method and
compared with the log-rank test. The incidence of TRM and GVHD was
calculated using an estimator of cumulative incidence curves. Patients were
censored at the time of death or last follow-up. Predictive analyses for the
event (PLS, PRABO, or AIHA) were performed using logistic regression.
Factors analyzed were ATG, diagnoses, graft type, donor type, disease
stage, GVHD prophylaxis, conditioning, GVHD, donor age, granulocyte
colony-stimulating factor (G-CSF) after HSCT, herpes virus serology, and sex
mismatch. Continuous variables were compared with the Mann-Whitney U
test or Kruskal-Wallis ANOVA and categorical variables using Fisher’s exact
test or chi-square test. Analysis was performed using the cmprsk package
(developed by Gray, June 2001), S-Plus 6.2 software (Tibco software, US),
and the Statistica software (Statsoft, US, MA).RESULTS
ABO Incompatibility and Effect on HSCT Outcome
The 310 patients transplanted with RIC were divided into
3 groups based on ABO compatibility (Table 1). Bidirectional
ABOmismatches were included in the major ABOmm group.
The only signiﬁcant difference between the patients groups
was the incidence of nonmalignant disease (P< .05). Patients
with minor and major ABO incompatibility required signiﬁ-
cantly more RBC transfusion at both 2 and 12 most post-
HSCT compared with the ABO-matched group (Table 2).
Furthermore, there were an increased number of platelet
transfusions 2 months post-HSCT for patients with major
ABO incompatibility (P < .05, Table 2). No signiﬁcant differ-
ences were observed between the ABO-matched and -mis-
matched groups in OS, TRM, acute GVHD grades II to IV,
chronic GHVD, or graft failure by multivariate analysis
(Supplemental Table 1).
Twenty-three patients with malignant disease and 12
with nonmalignant disease had graft failure. Seven patients
had a mismatched unrelated donor, 21 had a matched un-
related donor, and 7 had sibling donors. Nonmyeloablative
conditioning was used in 9 patients and RIC in 26. Five pa-
tients received cord blood, 20 peripheral blood stem cells,
and 10 bone marrow. These data indicate that the overallTable 2
ABO Compatibility and Transfusion Requirement
ABO RBCþ2 mo PLTþ2 mo RBCþ1 yr PLTþ1 yr
ABO match 2 (0-34) 1 (0-48) 4 (0-98) 4 (0-77)
Minor ABO mm 4 (0-50)** 1 (0-31) 9 (0-88)** 3 (0-74)
Major ABO mm 5 (0-45)*** 2 (0-41)* 8 (0-282)** 4 (0-115)
Kruskal-Wallis P < .001 P ¼ .08 P ¼ .002 P ¼ .19
PLT indicates platelet infusion.
Numbers indicate the median times of infusion per patient.
* P < .05, **P < .01, ***P < .001 versus ABO match.clinical outcome does not differ when transplanting across
the ABO blood barrier. Next, we investigated each hemolytic
complication that could arise from ABO-incompatible
transplants.
AIHA
Twelve patients (4%) were identiﬁed with AIHA post-
HSCT. AIHA was not associated with a decrease in OS or in-
crease in TRM (Figure 1A,B). However, patients with AIHA did
not experience any acute GVHD grades II to IV, which was
signiﬁcantly lower than patients without AIHA (P ¼ .04,
Figure 1C).
The following risk factors for AIHA development could be
identiﬁed by univariate analysis; use of ATG (P < .01), stem
cells from unrelated donors (P ¼ .047), and younger donor
age (<38 years) (P ¼ .03). Recipients seropositive for 0 to 2
herpes viruses before HSCT were more likely to develop
AIHA than patients positive for 3 to 4 herpes viruses (P¼ .02).
The incidence of acute GVHD in AIHA patients was lower
compared with patients without AIHA (P ¼ .006) (Table 3).
In the multivariate analysis, only patient virus serology
before HSCT was signiﬁcantly associated with AIHA (odds
ratio, .22; 95% conﬁdence interval, .06 to .8; P ¼ .02). There
was also a strong trend for the use of an unrelated donor as a
risk factor for AIHA (odds ratio, 7.38; 95% conﬁdence interval,
.92 to 59.5; P ¼ .06) (Supplemental Table 2). It was not
possible to analyze the effect of ATG and acute GVHD because
all AIHA cases received ATG and had no acute GVHD. There
was no effect on the incidence of AIHA dependent on
whether peripheral blood stem cells or bone marrow was
used.
PLS
Six patients fulﬁlled the criteria for PLS by having donor
type anti-ABO antibodies detected in plasma or on the RBCs
within 1 month post-HSCT. Survival in PLS patients was 0%
compared with 61% of patients without PLS (P < .001)
(Figure 2A). There was no difference in TRM in PLS patients
compared with patients without PLS (33% versus 22%, ns,
Figure 2B). Risk factors for PLS in univariate analyses were
transplants with unrelated donors (P ¼ .02), the absence of
methotrexate (P ¼ .03), and nonmyeloablative conditioning
for solid tumor (P ¼ .016) (Table 4). A multivariate analysis
was not possible because all PLS patients had an unrelated
donor and received ATG. The causes of death were progres-
sive disease of solid tumor (n ¼ 4) and pneumonia (n ¼ 2).
There was no effect on the incidence of PLS depending on
which graft source was used.
PRABO after Major ABO mm HSCT
Of the 95 patients who received a major ABOmismatched
HSCT, 12 patients had anti-A/B antibodies detectable
>3 months post-transplant and hence were classiﬁed as in-
dividuals with PRABO. Patients with PRABO had a signiﬁcant
number of complications post-HSCT. They had a greatly
decreased 3-year survival (17% versus 73%, P ¼ .002)
(Figure 3A), a signiﬁcantly higher TRM (50% versus 21%,
P ¼ .03) (Figure 3B), and more RBC and platelet transfusion
needs (Table 5) compared with patients without PRABO
receiving a major ABO mm HSCT.
The clinical picture of these 12 patients is as follows.
Three had indicators consistent with that of pure red cell
aplasia, that is, low reticulocyte count in peripheral blood,
normal lactate dehydrogenase, and normal or subnormal
numbers of platelet. Two patients had normal or high cell
Figure 1. AIHA and the impact on clinical outcome. There is no signiﬁcant
difference in (A) OS or (B) TRM in patients with AIHA compared with patients
without. Patients with AIHA have signiﬁcantly more (C) GVHD grades II-IV
than patient without.
Table 3
Risk Factors for AIHA, Univariate Analysis
Risk Factor Not Present Present P
URD 1/127, <1% 11/183, 6.0% .047
ATG 0/82 12/228, 5.3% <.001
Malignant disease 5/63, 7.9%
(nonmalignant)
7/247, 2.8% .07
Cord blood graft 10/296, 3.4% (BMþPBSC) 2/14, 14.3% .06
aGVHD grades I-IV aGVHD 12/148, 8.1% aGVHD 0/162 .006
Donor age 38 yr 4/37, 10.8% >38 yr 7/264, 2.7% .03
Recipient herpes
Virus serology*
0-2: 4/37, 10.8% 3-4: 7/264, 2.7% .02
URD indicates unrelated donor; aGVHD, acute graft-versus-host disease;
BM, bone marrow; PBSC, peripheral blood stem cells.
* Number of positive serology tests for different herpes viruses in recip-
ient before HSCT (0-2 versus 3-4). The ﬁgures indicate number of AIHA/total
patients in the group.
Figure 2. PLS and the impact on clinical outcome. Patients with PLS have a
signiﬁcantly lower (A) OS survival, but there is no difference in (B) TRM.
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or high levels of reticulocytes in peripheral blood, high levels
of lactate dehydrogenase, and low levels of platelets. He-
molysis resolved in these 2 patients without speciﬁc treat-
ment other than ABO-compatible RBC and platelet
transfusions. The remaining 7 patients presented withvarying degrees of hemolysis, poor marrow function with
mixed chimerism, and/or cytomegalovirus infections. Four of
these patients were transplanted due to solid tumors. Two
also had HLA antibodies and unspeciﬁc anti-RBC
autoantibodies.
Table 5
Transfusions for Patients with PRABO after Major ABO mm HSCT
RBC þ 2 mo PLT þ 2 mo RBC þ 1 yr PLT þ 1 yr
No recipient type ABO
ab (n ¼ 70)
4 (0-45) 2 (0-27) 6 (0-282) 2 (0-115)
Recipient type ABO ab
(PRABO) (n ¼ 12)
11 (0-42) 6 (0-41) 44 (6-92) 14 (0-70)
P .013 .06 <.001 <.001
PLT indicates platelet infusion; ab, antibodies.
Values are the median (range) of infusion units per patient.
Table 4
Risk Factors for PLS, Univariate Analysis
Risk Factor Not Present Present P
Unrelated donor 0/28 6/56 .02
ATG 0/19 6/65 .07
Solid tumor 2/58 4/26 .07
Methotrexate 4/22 2/62 .03
NMT 4/77 (RIC) 2/7 .043
NMT þ solid tumor 4/79 2/5 .015
NMT indicates nonmyeloablative conditioning (ﬂudarabine þ 2 Gy TBI).
Values indicate number of PLS/total patients in the group.
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factor identiﬁed by univariate analysis for PRABO after major
ABO mm HSCT (P ¼ .04). There was also a trend for PRABO in
patients treated for solid tumors (P ¼ .06) (Supplemental
Table 3). There was no effect on the incidence of PRABO
dependent on which graft source was used.
Of the 3 patients with classic pure red cell aplasia, 1 died of
progressive disease of solid tumor and 1 of a fungal infection.
Of the remaining 7 patients, 2 died of progressive disease of
solid tumor and 1 each from hemolytic uremic syndrome/Figure 3. Patients with PRABO after major ABO mm HSCT have a signiﬁcantly
lower (A) OS and (B) higher risk of TRM.thrombotic thrombocytopenic purpura, EBV lymphoma,
multiorgan failure, pneumonia, and rejection. No correlation
was found between PRABO and titer of anti-A/anti-B anti-
bodies in recipient plasma before HSCT (data not shown).DAT-Positive Post-ASCT
Positive DAT post-HSCT was more prevalent in patients
receiving ABO-incompatible than -compatible graft HSCT
(P ¼ .001). A positive DAT in itself did not signiﬁcantly affect
outcome as determined by OS, TRM, and graft failure.DISCUSSION
The clinical impact of ABO mm between donor and
recipient after HSCT is debated [8-11,14,35,36]. In our study,
we found a higher and prolonged need of RBC and platelet
transfusions after HSCT in patients with grafts from major
ABO mm donors compared with those with ABO-identical
donors (Table 2). This increased requirement of blood
transfusion was also observed in patients with a minor ABO
mm early after transplantation. Despite these increased
needs for blood transfusions, no signiﬁcant differences in
clinical outcome were identiﬁed between ABO matched and
mismatched HSCT (Supplemental Table 1).
AIHA is independent of ABO match between donor and
recipient [18]. AIHA did not provide an increased risk for
TRM or inferior OS. Interestingly, the 12 AIHA patients had a
signiﬁcantly lower risk of developing moderate-to-severe
acute GVHD (Figure 1). AIHA is caused by antibodies pro-
duced by the donor’s immune system against donor RBCs
and is rarely observed after HSCT. In our study, identiﬁed
risk factors for development of AIHAwere unrelated donors
and patient seropositivity for less than 3 herpes viruses
(Table 3). Patients with sibling donors, absence of both
ATG and acute GVHD, had a decreased risk of AIHA devel-
opment. Previous studies reported that unrelated donors
confer an increased risk of AIHA [18]. The use of unrelated
donors and virus serology was also signiﬁcant in multivar-
iate analysis (Supplemental Table 2). Because all unrelated
donors were treated with ATG, it was not possible to
analyze this factor in multivariate analysis. Viral reac-
tivation after HSCT is primarily controlled by natural killer
cells and effector T cells. In our study, patients with positive
serology before HSCT for 0 to 2 herpes viruses compared
with 3 to 4 had a higher risk of AIHA. Logically, individuals
with less prior virus exposure will have a higher risk of a
primary infection after HSCT. It has been shown that a
strong T cellemediated immune activation can lead to
autoimmune diseases due to both molecular mimicry and
bystander activation (reviewed in [37]).
That all patients with AIHA lack the occurrence of acute
GVHD is difﬁcult to explain. It can be speculated that either
the acute GVHD per se or the following corticosteroid
treatment and prolonged immune suppression inhibited B
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topic to our knowledge. Although ATG and acute GVHD could
not be analyzed by multivariate analysis, it might also be
possible that acute GVHD is merely dependent on the pres-
ence of ATG.
For the association between GVHD, herpes virus serology,
and AIHA, we can speculate that among herpes viruses, EBV
is harbored in B cells. Herpes virus antigens may also be a
stimulus for alloreactivity with induction of acute GVHD and
the corresponding graft-versus-autoimmune effect with
elimination of antibody-producing cells and hence
decreasing the risk of AIHA [38,39].
PLS is an antibody-mediated lysis of RBCs that can occur
afterminor ABOmmHSCTor organ transplantation [40]. It was
previously reported after both liver transplantations [41] and
HSCT [42,43] that cyclosporine alone gives rise to more he-
molysis due to PLS than if cyclosporine is used in combination
with methotrexate. This ﬁnding is also veriﬁed in our study
were theabsenceofmethotrexate isa risk factor forPLS (P¼ .03)
(Table 4). The introduction of peripheral blood stem cells as
graft source in combination with RIC increased the donor
lymphocyte dose and the period of donor and recipient he-
matopoietic cells interacting. RIC also increased the frequency
of PLS compared with myeloablative conditioning [19,44].
Severe hemolysis due to PLS has been described in pa-
tients requiring not only transfusions but also treatments
such as plasma exchange and blood exchange [2]. The inci-
dence of PLS was 7% (n ¼ 6) in this study with a 0% 1-year
survival (Figure 2). However, 4 patients with PLS were
transplanted due to solid tumor where overall results in
general are poor. Clinical signs of hemolysis post-HSCT in PLS
patients were absent or minor within the ﬁrst month or not
present at all (data not shown). This suggests that screening
for PLS during the ﬁrst month post-HSCT to anticipate he-
molysis as part of pretransfusion compatibility testing might
be unnecessary.
PRABO incidence after a major ABO mm HSCT in our pa-
tient material was 12%, and these patients had a higher rate
of TRM and lower rate of OS (Figure 3) compared with other
patients with a major ABO mm HSCT without PRABO.
Furthermore, these patients required more RBC and platelet
transfusions after HSCT (Table 5). G-CSF usage was the only
risk factor identiﬁed correlating with PRABO incidence
(Supplemental Table 3). The use of G-CSF in patients after
HSCT was previously associated with an increased risk for
acute and chronic GVHD [45]. In addition, data from a mouse
model showed that G-CSF induced natural killer T
celledependent alloreactivity and exacerbated GVHD after
bonemarrow transplantation [46]. The conditioning regimen
increased host dendritic cell G-CSF receptor expression,
stimulating a cascade of events that led to acute GVHD. The
observation that G-CSF was associated with an increased
occurrence of PRABO aftermajor ABOmmHSCT in our cohort
was unexpected because G-CSF induces GVHD, which readily
targets remaining cells of the recipient lymphoid system
(including B cells). Therefore, a decreased incidence of
recipient ABO antibodies upon G-CSF administration could
have been expected. A possible explanation may be found in
themultifaceted role of G-CSF in the immune system. Among
other things, administration of G-CSF lowers the production
of tumor necrosis factor-a, IL-2, and interferon-g. In addition,
it has been shown that G-CSF polarizes donor T cells to
produce anti-inﬂammatory type 2 cytokines [47-49].
In our study, 3 patients with PRABO expressed more
traditional signs associated with pure red cell aplasia. Purered cell aplasia after HSCT is associated with major ABO
incompatibility between donor and recipient [20,50].
Treatments with rituximab, donor plasma exchange, and
donor lymphocyte infusions have been tried successfully at
other centers [51-53].
Two of the 12 PRABO patients had a normal or elevated
cell number in the marrow together with clinical signs of
hemolysis and normal to high reticulocyte count in periph-
eral blood. These 2 patients were the only PRABO patients
alive at the end of the study. They were found to have a su-
perior marrow function compared with the deceased
patients.
In the entire major ABO incompatibility group, there was
an increased need for both RBCs and platelets. In the PRABO
group, individuals with clinical hemolysis required both RBC
and platelet transfusions. Because platelets also express ABO
antigens, the increased platelet requirement may be due to
residual recipient ABO antibodies.
A positive DAT post-HSCT was more common in patients
receiving ABO-incompatible than -compatible HSCT
(P ¼ .001), but this did not signiﬁcantly affect outcome (OS,
TRM, graft failure). Although patients receiving ABO-
incompatible grafts received more blood transfusions, there
were no signiﬁcant differences in clinical outcome compared
with ABO-compatible recipients (Supplemental Table 1).
It has to be taken into account that this is a retrospective
analysis over several years. Minute, unnoticed, but still
pivotal changes in supportive care, infection treatments, and
prophylaxis can be confounding factors. The transfusion re-
quirements in the groups were expressed as the number of
transfused units; individual differences in body weight and
content of blood products were not included in the analysis
because those variables were not available.
The results from this study with patients undergoing RIC
HSCT indicate that the overall clinical outcome does not
differ when transplanting across the ABO. Although we still
see, albeit rare, antibody-mediated complications associated
with an ABO mm, an ABO matched donor may still be
preferred when several otherwise equal unrelated donors
are found.
In summary, unexpected donor type ABO antibodies
present early after minor HSCT (PLS) or recipient type ABO
antibodies detected later in major ABO mm HSCT (PRABO)
were associated with inferior OS and higher TRM. Further
studies are needed to elucidate the immunological mecha-
nisms because ABO mm, in itself, did not affect clinical
outcome. These results suggest that occurrence of unex-
pected ABO antibodies after HSCT could warrant a wider
investigation of the individual patient’s condition to ﬁnd the
underlying cause and improve survival.
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